Actionable news
All posts from Actionable news
Actionable news in BMRN: BioMarin Pharmaceutical Inc.,

Summit moving ahead with DMD candidate, mid-stage study sites expand to the U.S.

UK-based Summit Therapeutics (NASDAQ:SMMT) has a bit of good news for Duchenne muscular dystrophy (DMD) investors who are about to bloodied today if they are holding shares in Sarepta Therapeutics (NASDAQ:SRPT). The FDA has cleared its Investigational New Drug (IND) application for DMD candidate ezutromid (formerly SMT C1100) which clears the way to recruit U.S. trial...